Virginia Cancer Specialists Practice Blog

January 02, 2024

Endocrine therapy remains a mainstay in the treatment of early-stage hormone receptor-positive breast cancer. However, oncologists continue to work on improving the risk of recurrence in patients whose tumors exhibit high-risk features, such as a larger size or lymph node involvement.

The MonarchE trial, a randomized phase 3 trial in adults, examined how the addition of abemaciclib to standard endocrine therapy could improve outcomes in high-risk early stage hormone receptor-positive breast cancer. Abemaciclib is an oral medication that is already used in metastatic hormone receptor-positive breast cancer but is new to the space of early-stage breast cancer. In contrast to standard endocrine therapy, abemaciclib targets estrogen-based signaling pathways that allow cancer growth and proliferation.

The investigators found that the addition of abemaciclib to standard endocrine therapy in these higher-risk patients improved how long patients remained disease free and alive (an absolute difference of 6.4% – 79.4% in the endocrine therapy alone group, and 85.8% in the abemaciclib + endocrine therapy group). Given how frequently breast cancer impacts our communities, this difference is significant and an exciting improvement and option for our patients.

With any addition of therapy, it is imperative to consider potential side effects. Patients who received both endocrine therapy and abemaciclib had higher rates of neutropenia and diarrhea, although most of these side effects were manageable with proper supportive care and monitoring. Like anything else, these side effects are something we discuss and need to personalize for each patient. In addition to abemaciclib, many similar class drugs are being examined (such as ribociclib) in this setting, further improving the options available to our patients.

Related Posts

Advancements in Treating Chemotherapy Side Effects – A New Standard of Care for Preventing Hand-Foot Syndrome - Igryl S. Cordero, MD

Igryl S. Cordero, Breast Cancer, GI Cancer
October 19, 2023
Read More

Dr. David Weintritt Brings Innovative Treatment to Breast Cancer Patients in Northern Virginia

David Weintritt, Breast Surgery Services, Breast Cancer, Breast Cancer Team, Press Releases
October 3, 2022
Read More

Navigating Breast Cancer as a Young Adult - Virtual Workshops

Breast Cancer, Social Work
January 20, 2022
Read More

What’s the NEW Virginia Cancer Specialists Breast Cancer Lifestyle Action Group? How Can You Engage?

Breast Cancer, Nutrition
November 5, 2019
Read More

Virginia Cancer Specialists Enhances World-Class Breast Surgery Services with the Addition of Breast Surgeon Elizabeth Feldman, MD

FACS, Breast Surgery, Breast Cancer
July 11, 2019
Read More

Dr. Patricia Rodriguez speaks at Tigerlily’s 6th Annual Young Women’s Breast Health Day on the Hill

Genetic Risk Assessment, Breast Cancer, Patricia Rodriguez MD
May 8, 2018
Read More